Outcomes Comparison of the Veterans' Choice Program With the Veterans Affairs Health Care System for Hepatitis C Treatment.

摘要: Background The US Department of Veterans Affairs (VA) has been stressed by the large number veterans requiring direct-acting antiviral (DAA) medications for hepatitis C virus (HCV) treatment. Choice Program provides VA patients more options to receive This study compared experience who received HCV treatment through and those that at Loma Linda Healthcare System (VALLHCS) in fiscal year (FY) 2016. Methods A chart review was performed on all referred VALLHCS during FY 2016, matched VALLHCS. Data collected included Fibrosis-4 score (Fib-4), platelet count, days elapsed between time referral appointment (wait time), rate sustained virologic response 12 weeks (SVR12), reason failure, cost effectiveness. Results One hundred were Choice; 71 seen least once a provider, 61 completed course. Mean Fib-4 count 1.9 228,000 population 3.4 158,000 population, respectively. There no difference SVR12 rate. wait 42 vs 29 (P < .001). health care providers incurred mean $8,561.40 additional costs per veteran seen. Conclusions While success rates similar VALLHCS, degree liver fibrosis advanced population. longer with direct within VA. offers potential solution providing veterans, current program unique problems must be considered.